Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.
about
Combination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseA review of nebulized drug delivery in COPDAdvances in device and formulation technologies for pulmonary drug delivery.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.Nonhuman targets in allergic lung conditions.Advances in metered dose inhaler technology: formulation developmentThe PulmoSphere™ platform for pulmonary drug delivery.Understanding pressurized metered dose inhaler performance.Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging StudyInhalation by design.Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technologyIsothermal Microcalorimetry of Pressurized Systems II: Effect of Excipient and Water Ingress on Formulation Stability of Amorphous Glycopyrrolate
P2860
Q27012625-C0CA2FBD-3B17-4D54-9759-B2711CE4904EQ28075295-8B585B9B-3613-4271-BA2A-EC12C5604CC4Q33962567-C8378B9A-2091-4BE7-896C-B3F1AA8719A4Q36356295-86B18F56-62BC-4908-8E9F-F34E1CB2AEDCQ38077545-1C4F23B7-CFFC-40BC-B6FF-083CB6B97F32Q38180975-4D67737B-BFFF-42D8-8B28-FC4C2F5CC949Q38193170-2E9AE067-D953-4B0F-B9DA-4330E79E934BQ38286400-46D3B5CF-117B-46D9-93E8-FDC40F23A51CQ38604619-0723BCF4-0036-4BA6-A13D-E428AAADFFA8Q51676366-4EE4D01B-CF3C-497D-8F1D-B5A8238246D2Q52614710-6F0C82BA-9E99-4EA0-A2CF-B2DA892BDA60Q53839703-F35AADB7-6375-4BF2-88FC-843DBA23D2F6Q55021618-3D0B0440-38C4-49F1-8F74-6882BEF64FF8Q55387524-82A0EF99-A19E-4FB9-8A43-F37032011FD6Q58759101-7F817753-A99A-4AEA-85BB-9768A475B239Q59291755-46D9F351-D468-4314-BEEA-99C821B5EA9D
P2860
Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@en
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@nl
type
label
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@en
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@nl
prefLabel
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@en
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@nl
P2093
P2860
P356
P1476
Novel cosuspension metered-dos ...... pulmonary disease and asthma.
@en
P2093
Brian Noga
David Lechuga-Ballesteros
R Harris Cummings
Sarvajna K Dwivedi
P2860
P304
P356
10.4155/FMC.11.133
P577
2011-10-01T00:00:00Z